# IBD Treatment Strategies

> IBD treatment strategies for NEET-SS Gastroenterology: treat-to-target STRIDE-II goals, steroid rules, thiopurine safety and pre-biologic screening.

- Canonical URL: https://prepelephant.com/topics/neet-ss/medical-gastroenterology/ibd-treatment-strategies
- Exam / course: NEET-SS · Subject: Medical Gastroenterology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "IBD Treatment Strategies", PrepElephant, https://prepelephant.com/topics/neet-ss/medical-gastroenterology/ibd-treatment-strategies

## Direct answer

Treat to a target, not to symptoms: current IBD strategy aims for clinical remission plus normalisation of C-reactive protein and faecal calprotectin plus endoscopic healing, because mucosal healing — not symptom relief — predicts steroid-free remission, hospitalisation avoidance and surgery avoidance. Corticosteroids induce remission but must never maintain it; the maintenance ladder runs from aminosalicylates (ulcerative colitis) through thiopurines and methotrexate to biologics and small molecules, chosen by severity, extent, prognosis and previous failures. Before any immunosuppressant, screen for latent tuberculosis, hepatitis B (with prophylaxis for HBsAg-positive patients on anti-TNF therapy), varicella status and give due vaccines; before thiopurines, check TPMT and NUDT15 — the NUDT15 variant that predisposes to severe myelosuppression is far commoner in South and East Asian populations than in Europeans, a genuinely Indian exam point. Combination anti-TNF plus thiopurine outperforms either alone in moderate-to-severe Crohn's disease.

## What you must remember

- **STRIDE-II targets:** clinical remission (patient-reported outcomes) plus biomarker normalisation (CRP, faecal calprotectin under roughly 150–250 micrograms/g) plus endoscopic healing, reassessed at defined intervals; growth and quality of life are additional goals in children.
- **Steroid law:** prednisolone 40 mg tapering over about 8–10 weeks, or intravenous hydrocortisone for severe disease, to induce remission only; steroid dependence (relapse on taper or within 3 months of stopping) mandates escalation to a steroid-sparing agent; budesonide MMX or ileal-release budesonide spare systemic exposure where topology allows.
- **Aminosalicylates:** oral mesalazine 2–3 g daily plus rectal therapy (suppository for proctitis, enema for left-sided disease) for mild-to-moderate ulcerative colitis; no proven maintenance benefit in Crohn's disease.
- **Thiopurines:** azathioprine 2–2.5 mg/kg or 6-mercaptopurine 1–1.5 mg/kg; onset of benefit 8–12 weeks; check TPMT and NUDT15 genotype before starting; warn about pancreatitis (first 3–4 weeks), myelosuppression (monitor counts, dose-adjust for NUDT15 R139C homozygotes, who may tolerate almost none) and hepatotoxicity; lymphoma risk is real but small, highest with combination therapy.
- **Methotrexate:** 25 mg subcutaneously or orally weekly with folic acid, an alternative maintenance agent for Crohn's disease; absolutely contraindicated in pregnancy.
- **Escalation logic:** early combined immunosuppression (biologic plus thiopurine) for poor-prognosis patients at diagnosis — young age, extensive disease, perianal disease, deep ulcers, high CRP — rather than the traditional slow step-up.
- **Pre-immunosuppression checklist:** latent TB screen (chest radiograph, tuberculin or IGRA; treat with antitubercular prophylaxis before anti-TNF), HBV serology (HBsAg positive — start entecavir or tenofovir prophylaxis), HCV and HIV status, varicella serology, complete vaccination including influenza, pneumococcal and hepatitis B before starting; live vaccines are withheld on immunosuppression.
- **Surgical triggers:** ulcerative colitis — dysplasia or carcinoma, refractory disease, toxic megacolon, perforation; Crohn's disease — fibrostenotic obstruction, abscess, fistula unresponsive to medical therapy; in India, always weigh intestinal tuberculosis, which both mimics Crohn's and is unmasked by immunosuppression.

## A worked escalation case

A 26-year-old presents with extensive ulcerative colitis, six bloody stools daily, CRP 42, calprotectin 1800. Admission as acute severe colitis (Truelove-Witts criteria), intravenous steroids, and day-3 assessment with the Oxford criteria decide the next branch — rescue infliximab or colectomy discussion. She responds, is discharged on a taper, but relapses within two months of stopping steroids: steroid-dependent disease. Now the target is explicit — endoscopic healing at 9–12 months, calprotectin under 250. Options are a thiopurine (slow, weak alone after steroid dependence), a biologic (anti-TNF, vedolizumab or ustekinumab), or combination; her young age, extensive disease and early severity argue for early biologic therapy with thiopurine co-prescription for immunogenicity reduction. Before the first infusion: TB screen, HBV status, vaccinations. Every escalation is justified against the target, and every target check is objective — that is what "treat-to-target" means operationally, and it is the framing NEET-SS uses for escalation questions.

## How the exam frames it

Stems hinge on four discriminations: steroid dependence versus steroid refractoriness (escalate in both, but refractory acute severe disease goes to rescue therapy within days); step-up versus top-down (prognostic factors choose); thiopurine safety in Indian patients (NUDT15 and early myelosuppression — a South-Asian pharmacogenetic favourite); and Crohn's versus intestinal tuberculosis before immunosuppression (ileocaecal disease with disproportionate lymphadenopathy, ascites, or positive AFB/TB-PCR tips toward tuberculosis; a diagnostic trial of antitubercular therapy is the last resort, never the first). The single most-tested principle remains: steroids never maintain remission.

## Frequently asked questions

### What end points define successful IBD treatment beyond symptoms?

Clinical remission plus CRP and faecal calprotectin normalisation plus endoscopic mucosal healing, with normal growth in children — the STRIDE-II treat-to-target framework.

### Why are corticosteroids never maintenance therapy?

They do not alter the natural history and their cumulative toxicity (diabetes, hypertension, osteopaenia, infection) is unacceptable; steroid dependence or refractoriness mandates transition to a steroid-sparing maintenance agent.

### What genetic test is particularly relevant before thiopurines in Indian patients?

NUDT15 genotyping — the R139C loss-of-function variant, common in South and East Asians, causes severe early myelosuppression and requires major dose reduction or avoidance; TPMT alone misses it.

### Which infections must be excluded or managed before anti-TNF therapy?

Latent tuberculosis (screen and treat before starting), chronic hepatitis B (antiviral prophylaxis for HBsAg-positive patients), and active bacterial or fungal infection; varicella status is checked and live vaccines avoided on therapy.

### When is top-down therapy preferred over step-up?

In poor-prognosis disease at presentation — young age, extensive or deep-ulcerating disease, perianal Crohn's disease, high inflammatory burden — where early combined immunosuppression prevents the accumulated damage of sequential failures.